Stocktoria

Valion Bio, Inc. VBIO

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-11-11

Valion Bio, Inc. statistics & valuation

Market cap$1.8M
P / B0.1×
Return on equity-52.9%
Return on capital-25.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
-3.00% 16.20% 24.40% 0.30% 20212022202320242025
Operating margin (%)
-448.10% -548.80% -701.10% -573.80% 20212022202320242025
Return on equity (%)
-64.00% -278.10% -230.30% -223.10% -52.90% 20212022202320242025
Shares outstanding
9.7M 96778 86241 556902 2.5M 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-56.50% -171.80% -159.90% -201.50% -28.10% 20212022202320242025
Free cash flow margin (%)
-485.30% -733.80% -734.00% 20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$2.43 -$104.32 -$176.80 -$19.68 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Gross margin—0.3%24.4%16.2%-3.0%
Operating margin—-573.8%-701.1%-548.8%-448.1%
Net margin—-725.0%-701.0%-548.7%-675.7%
FCF margin—-734.0%-733.8%-485.3%—
Return on assets-28.1%-201.5%-159.9%-171.8%-56.5%
Return on equity-52.9%-223.1%-230.3%-278.1%-64.0%
Current ratio20.139.703.322.8311.72

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.